Results 231 to 240 of about 7,676,849 (387)

Patient Reported Outcome Measurements in Adult Spinal Deformity: A Narrative Review. [PDF]

Global Spine J
Kelly MP, Smith JS, van Hooff M.
europepmc   +1 more source

PCN29: DEVELOPING A MEASUREMENT STRATEGY FOR PATIENT-REPORTED OUTCOMES: FINDINGS FROM THE NCI'S CANCER OUTCOMES MEASUREMENT WORKING GROUP

, 2003
C. Snyder, Justina Lipscomb, CC Gotay
openalex   +1 more source

Two-Year Clinical Outcomes After Enhanced External Counterpulsation (EECP) Therapy in Patients With Refractory Angina Pectoris and Left Ventricular Dysfunction (Report from the International EECP Patient Registry) [PDF]

, 2005
Özlem Soran, Elizabeth D. Kennard, Abdallah G. Kfoury, Sheryl F. Kelsey   +3 more
openalex   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

Adoption of electronic patient-reported outcomes in cancer clinical practice: the point of view of Italian patients

ESMO Real World Data and Digital Oncology
Background: In 2022, the European Society for Medical Oncology (ESMO) guideline recommended the adoption of electronic patient-reported outcomes measures (ePROMs) in routine clinical practice for patients with cancer.
A.A. Valsecchi, V. Battista, S. Terzolo, R. Dionisio, G. Lacidogna, D. Marino, V. Quarà, E. Sperti, V. Tuninetti, F. Vignani, C. Zichi, V.E. Bounous, G. Valabrega, A. Ferrero, N. Biglia, M. Di Maio   +15 more
doaj  

Variations in quantifying patient reported outcome measures to estimate treatment effect. [PDF]

World J Methodol
Muthu S, Vadranapu S.
europepmc   +1 more source

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

, 2004
Bertram L. Kasiske, Borja G. Cosío, Judith A. Beto, K Bolton, Blanche M. Chavers, Richard H. Grimm, Adeera Levin, Bassam A. Masri, Rulan S. Parekh, Christoph Wanner, David C. Wheeler, Peter W.F. Wilson   +11 more
openalex   +1 more source

Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139] [PDF]

, 2005
Jean‐Paul Ortonne, Neil H. Shear, Stephen Shumack, Eric Henninger   +3 more
openalex   +1 more source

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

Molecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche, Renske Imschoot, Béatrice Lintermans, Lode Denolf, Joachim Taminau, Charlotte Fieuws, Geert Berx, Kris Gevaert, Kathleen B. M. Claes   +8 more
wiley   +1 more source

The use of patient reported outcome measures (PROMs) in clinical assessment. [PDF]

, 2018
Black, Bradbury-Jones, Burton, Dawson, Drozd, Equality Act, Flynn, Goldbart, Harris, Haywood, Jette, Jones, Kavanagh, Kyte, MacArthur, Mansell, Murray, Nelson, RCN, Streiner, Wylde   +20 more
core   +1 more source